Tuesday November 20, 5:00 am Eastern Time
Press Release
SOURCE: Bioheart, Inc.
Bioheart Completes Additional Financing of $5 million

Bioheart Continues its Focus on Products for Regenerating Damaged Heart Muscle

FORT LAUDERDALE, Fla.--(BW HealthWire)--Nov. 20, 2001--Privately held Bioheart, Inc. has received an equity investment from Getz Medical, a division of Getz Bros. & Co., Inc., a leading marketing and distribution organization in the Asia Pacific Region focused on medical technologies for cardiovascular disease. Bioheart and Getz Medical have also entered into a long-term marketing and distribution agreement for the Asia Pacific Region. Additional participants in the completed $5 million round of financing included Ascent Medical Technology Venture Capital Fund and the previously announced investment by Guidant Corporation (GDT). Bioheart is focused on developing cellular-based therapies to regenerate heart muscle tissue.

``Receiving the investment from Getz and Ascent is a significant event, signaling the recognition by distributors and venture capital of the importance of biologics in the treatment of congestive heart failure and heart attack patients,'' said Howard J. Leonhardt, Chairman and CEO, Bioheart, Inc. ``We are committed to building relationships with respected and qualified partners in order to advance the development of Bioheart and our ability to meet our financial, clinical, and business objectives.'

' ``Getz Medical's investment in Bioheart, Inc. represents an important stride forward in developing our product and technology base for the future,'' said Ray Simkins, President of Getz Medical's operations. ``Bioheart's cell regeneration therapy is an exciting development in the treatment of patients who are suffering the effects of heart attack and heart failure, and fits strategically with our corporate objectives. We look forward to introducing and establishing Bioheart's technologies and products in Asia Pacific.''

Developing New Therapies to Treat Heart Patients
Bioheart's principal initial product under development is called MyoCell(TM), which is designed to regenerate damaged muscle tissue through the transplantation of skeletal muscle cells. Skeletal muscle cells are obtained during a biopsy then expanded through a proprietary process over three to four weeks. Myoblasts (young muscle cells) are transplanted back into the patient's damaged heart using Bioheart's proprietary delivery device. The first patient was treated with MyoCell in May 2001 in Europe, and Bioheart plans to begin human testing in the United States later this year.

Heart muscle regeneration has been proposed as a treatment option for heart attack patients, since the adult heart cannot regenerate damaged muscle tissue on its own. Survivors of large or severe heart attacks in which part of the heart muscle dies can subsequently suffer from congestive heart failure as the damaged heart muscle causes the heart to pump inefficiently.

Karl Groth, Managing Director Ascent Medical Technology Venture Capital Fund said, ``Ascent remains committed to early identification of future growth opportunities focused in the cardiovascular area. It is our hope that Ascent's investment in Bioheart and this emerging area will help make the potential benefits of this treatment available to patients sooner. The clinical application of the MyoCell product offers a significant market opportunity and we are excited to be participating in this round of financing.''

About Bioheart, Inc.
Bioheart, Inc. is focused on the discovery, development and commercialization of cellular-based products for the treatment of cardiovascular diseases, including heart attack (myocardial infarction), congestive heart failure and angina pectoris. For more information about Bioheart, please visit http://www.bioheartinc.com.

About Getz Bros & Co., Inc.
Getz Medical is a leading international marketing, distribution and services company, focused on providing a wide range of medical devices, medical equipment, and branded pharmaceutical products in over 20 countries in Asia Pacific. Getz Bros. & C., a member of The Marmon Group of companies, is headquartered in Chicago, Illinois and has over 2,000 worldwide employees. For more information about Getz Medical, please visit http://www.getzmedical.com or http://www.marmon.com.

About Ascent Medical Technology Venture Capital Fund
Ascent Medical Technology Venture Capital Fund is a $100 million fund formed in 1999 by Ascent/Meredith Asset Management, a New York-based investment management firm. Ascent's strategy is to acquire equity at attractive prices in companies with innovative medical technologies.

About Guidant Corporation
Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to 7 million cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of 10,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. For more information visit http://www.guidant.com.

This release contains certain forward-looking statements, which are based on management's current expectations and are subject to uncertainties, risks and changes in circumstances, many of which involve factors or circumstances beyond Bioheart's ability to control. These factors, risks and uncertainties could cause actual results to differ materially from historical results or those expected, estimated or anticipated in the forward-looking statements. The forward-looking statements in this release include statements addressing the following subjects: Bioheart's products under development, and research studies related to technology upon which Bioheart's products are based; potential markets and applications for Bioheart's products; human testing of Bioheart's products, and beliefs that the application of Bioheart's products to human patients may be medically or commercially successful; and Bioheart's ability to achieve its financial and business objectives. The forward-looking statements included in this press release are made as of the date hereof, and Bioheart undertakes no obligation to update or revise any such statements, whether as a result of new developments, new information or otherwise.

Contact:
Bioheart, Inc., Fort. Lauderdale
John L. Babitt, 954/217-7259
jlbabitt@bioheartinc.com